Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

FDG PET/CT and breast cancer

By Kristin Schmiedehausen, MD

|2015-01-02

Breast cancer is the most common cause of cancer death in women.1 PET/CT using Fludeoxyglucose F18 injection (18F FDG) can impact staging and restaging of breast cancer, especially in patients with inflammatory, locally advanced and metastatic breast cancer. Download the white paper to learn about the increasing role PET/CT has in breast cancer in addition to breast cancer treatment guidelines and reimbursement options for certain countries.

1